| 前收盘价格 | 0.920 |
| 收盘价格 | 0.929 |
| 成交量 | 373,734 |
| 平均成交量 (3个月) | 498,315 |
| 市值 | 65,714,716 |
| 价格/销量 (P/S) | 840.89 |
| 股市价格/股市净资产 (P/B) | 1.22 |
| 52周波幅 | |
| 利润日期 | 19 Mar 2026 |
| 营业利益率 (TTM) | -41,252.01% |
| 稀释每股收益 (EPS TTM) | -0.870 |
| 季度收入增长率 (YOY) | 103.60% |
| 总债务/股东权益 (D/E MRQ) | 1.00% |
| 流动比率 (MRQ) | 5.28 |
| 营业现金流 (OCF TTM) | -47.70 M |
| 杠杆自由现金流 (LFCF TTM) | 34.37 M |
| 资产报酬率 (ROA TTM) | -34.47% |
| 股东权益报酬率 (ROE TTM) | -54.13% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | InflaRx N.V. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 3.5 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 5.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 2.13 |
|
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 6.44% |
| 机构持股比例 | 26.24% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Dcf Advisers, Llc | 31 Dec 2025 | 158,500 |
| 52周波幅 | ||
| 中 | 6.00 (518.56%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 30 Dec 2025 | 6.00 (518.56%) | 购买 | 1.02 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合